DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, drugs capable of inhibiting the DPP4 dipeptidyl peptidase catalytic activity, which are currently FDA-approved for treatment of diabetes[32], may have utility in targeting CML LSCs.